Steven Stein, Chief Medical Officer at Incyte, shared a post on LinkedIn:
“Today, two of Incyte’s oncology treatments were approved in Japan – one for patients with follicular lymphoma and another for patients with squamous cell carcinoma of the anal canal. This significant milestone underscores our commitment to delivering transformative therapies to patients around the world.
Thank you TeamIncyte for your dedication to making an impact for patients.”
More posts about Cancer Treatment.